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Microscopic Satellites Around a Primary Melanoma: Another
Piece of the Puzzle in Melanoma Staging
Charles M. Balch, MD, FACS
Departments of Surgery, Oncology and Dermatology, Johns Hopkins Medical Institutions, Baltimore, MD
This is an important subject that is applicable to surgical
treatments of the primary melanoma and the regional
lymph nodes as well as melanoma prognosis and staging.
The importance of cancer staging, of course, is to partition
patients into risk groups based upon disease-specific sur-
vival rates. In turn, the converse of survival rates at 5 or
10 years reflects the incidence of distant microscopic
metastases at the time of staging from which a patient
would ultimately succumb. With respect to the nodal (N)
classification in melanoma, the two most important prog-
nostic features are number of nodal metastases (1 versus 2/
3 versus C4) and tumor burden (i.e., microscopic or clin-
ically occult versus macroscopic or clinically apparent
nodal metastases).1,2 The third criterion for defining the N
category is the presence or absence of satellites or in transit
metastases, regardless of the number of lesions. The clin-
ical presence of satellites around a primary melanoma or of
in-transit metastases between the primary melanoma site
and the regional lymph node basin represent intralymphatic
metastases that portend a relatively poor prognosis.3–5 The
available data show no substantial difference in survival
outcome for these two anatomically defined entities.3
But what about microscopic satellites? These are defined
as any discontinuous nest of intralymphatic metastatic cells
[0.05 mm in diameter that are clearly separated by normal
dermis (not fibrosis or inflammation) from the main inva-
sive component of melanoma by a distance of at least
0.3 mm.2,6 In the past, the definition of microsatellites has
varied, and this may account for some of the differences in
results regarding their prognostic significance. As a result,
the level of evidence regarding the prognostic significance
of microsatellites is less robust, but the available data
indicates that this is an adverse finding associated with an
increased risk of regional recurrences and a decreased
disease-free survival rate similar to that of clinically
detectable satellites.7–12 Whether microsatellites represent
an independent predictor of survival outcome is less clear,
but at present the preponderance of evidence suggests that
this feature represents an adverse prognostic factor for
survival. Accordingly, the America Joint Committee on
Cancer (AJCC) Melanoma Staging Committee has rec-
ommended that this feature of early lymphatic metastases,
as defined above, be retained in the category of N2c
melanoma.2,6
This issue of the Annals of Surgical Oncology includes a
valuable contribution to our decade-long work on mela-
noma staging as regards microsatellites.13 In this setting,
the AJCC Melanoma Staging Database did not have direct
data that could be applied to the staging rules for patients
with microscopic satellitosis, except that published in the
literature, much of which was published years ago.7–12 This
study by Kimsey and colleagues from Memorial Sloan–
Kettering Cancer Center (MSKCC) was made possible by
the commitment made through the years by MSKCC sur-
geons to collect prospective data on their melanoma
patients, which now includes almost 4,000 prospectively
followed patients.13 Among these patients was a carefully
studied cohort of 38 patients with newly diagnosed, clini-
cally localized melanoma containing microscopic
satellitosis. These primary melanomas had very aggressive
features, including a median thickness of 5.4 mm and the
majority (71%) being ulcerated. The 5-year overall and
disease-free survival rates in these patients were 34% and
18%, respectively, and 68% had pathologically involved
regional nodal metastases. They clearly constitute a high-
risk group of patients for both regional and distant metas-
tases that needs to be accounted for in our staging rules.
In the 6th edition of the Cancer Staging Manual, the
Melanoma Staging Committee modified its staging criteria
 Society of Surgical Oncology 2009
Published Online: 27 February 2009
C. M. Balch, MD, FACS
e-mail: balchch@jhmi.edu
Ann Surg Oncol (2009) 16:1092–1094
DOI 10.1245/s10434-009-0353-4
by incorporating both microscopic and clinically detectable
satellites and/or in-transit metastases without concomitant
lymph node involvement into the same nodal classification
as patients with two or three metastatic lymph nodes (N2c,
stage IIIB).1,14 Patients with nodal intralymphatic metas-
tases plus nodal metastases clearly have a worse prognosis
and are therefore classified in a separate category when the
regional lymph nodes contained metastatic melanoma (N3,
stage IIIC). This decision was based upon the older liter-
ature cited above. As we finalized the melanoma staging
criteria for the 7th edition of the Cancer Staging Manual,
the Melanoma Staging committee debated whether or not
to continue this criterion for this small, but definable group
of patients with microsatellites. A decision was made to
retain these staging rules, and the data from the MSKCC
Melanoma Database offers contemporary results to support
this decision.2,6 In addition, their results make a compelling
case for performing sentinel node biopsy in those patients
with clinically negative regional nodes, since 71% of such
patients had microscopic nodal metastases.
In this rather small sample of patients with microscopic
satellites, the impact of nodal status was profound. Thus,
patients with microsatellites around the primary melanoma
and pathologically negative sentinel node had 5-year sur-
vival of 60%, while none of those patients with
microsatellites and nodal metastases lived more than 5 years
(p = 0.02). These survival results are similar to that in a
larger sample size from the 2008 AJCC Melanoma Staging
Database which contained new information about 399
patients with intralymphatic metastases and negative nodes
(N2c).2 The 5-year survival rate was 69%, similar to that
reported in the MSKCC study. These are somewhat more
favorable survival rates than previously reported in the lit-
erature, and higher than for the remaining cohort of stage
IIIB patients (54% at 5 years).3 Nonetheless, the AJCC
Melanoma Staging Committee noted that the category of
stage IIIB was presently the closest fit and recommended
that the 6th edition staging definition be retained.2,6
Finally, the authors make comparisons of a very small
number of patients with metastases in the sentinel node but
who, for reason not explained, did not have completion
lymphadenectomy. The survival rate of these patients was
no different from those who did have completion lym-
phadenectomy. Since most all of these patients eventually
died of distant metastases, the lack of survival differences
is not surprising. In a retrospective analysis like this, and
without knowing more about the clinical decision making
that led to some patients not having completion lymphad-
enectomy, it would be difficult to make any conclusions
about any survival benefit of lymphadenectomy in these
high-risk patients. Even in those circumstances where
survival rates are not increased, there may still be a justi-
fication for completion lymphadenectomy to achieve
regional disease control, although the benefit–risk indica-
tions should be higher in this circumstance.15 The issue of
completion lymphadenectomy is still a debated subject, as
evidenced by the results from the National Cancer Data-
base that only 50% of patients with biopsy-proven
metastases in the USA have completion lymphadenectomy
as recommended in national melanoma guidelines.16
What are the implications for surgical excision of pri-
mary melanoma? Our present approach is to excise a
margin of normal skin and underlying subcutaneous tissues
to incorporate the primary melanoma and lymphatics
immediately surrounding the melanoma to prevent sub-
sequent development of a local recurrence, defined as
tumor within 2 cm of the surgical scar. The appearance of a
local recurrence after appropriate wide excision of a mel-
anoma is usually associated with aggressive tumor biology
of the primary melanoma (i.e., increased thickness and
mitotic rate, ulceration) and is a harbinger of fatal metas-
tases in the majority of such patients. An interesting
speculation is that intralymphatic satellites around a pri-
mary melanoma have a role in the subsequent development
of ‘‘local recurrences.’’ The survival rates of such patients
with local recurrences are virtually the same as those with
intralymphatic metastases.17 One could hypothesize that
local recurrences are, in fact, a manifestation of intralym-
phatic disease, not of retained primary melanoma cells that
grow back with an unusually aggressive biological capacity
for metastases. This explanation is a much more logical
rationale for why we perform a wide excision of normal-
appearing skin surrounding a primary melanoma, that is, to
excise microsatellite metastases that are usually not
detected without serial sectioning of the primary mela-
noma. It is interesting that, in the entire MSKCC database
of 3,753 patients, there were 162 (4.3%) with microscopic
satellitosis in their primary melanoma, most of whom had
clinically evident regional or distant metastases. The
results of this study clearly demonstrates the importance of
performing sentinel node biopsy in those patients without
clinical or radiological evidence of nodal metastases, since
about 70% of such patients will, in fact, harbor clinically
occult nodal metastases. More knowledge about the true
incidence of microsatellites and their distance from pri-
mary melanomas of varying T stage might help in the
design of future clinical trials to determine what width of
surgical margins will prevent the development of a fatal
local recurrence later on.
Finally, the melanoma surgeons at MSKCC, like others
who have maintained prospective cancer databases through
the years, are to be commended for their continued
investment in this valuable resource. These prospective
databases enable us to examine specific details of patient
management that are useful in the staging, prognosis, and
treatment outcomes of our patients.
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